When does the doxorubicin patent expire?
For traditional generic doxorubicin, the active ingredient is decades old, so patent protection has largely run out and multiple generic versions are already available. In practice, the “patent expiration year” depends on the specific patent(s) tied to a particular manufacturer’s formulation (for example, a branded liposomal doxorubicin product or a specific delivery/formulation technology), not on doxorubicin as a whole.
Does doxorubicin have one single patent expiration year?
No. “Doxorubicin” can refer to different drug products that have different patent estates:
- Generic doxorubicin hydrochloride (older, widely available): patents on the original compound are long expired.
- Branded or specialty formulations (examples often include liposomal doxorubicin): these can have separate patents on the formulation, device/technology, manufacturing process, or additional indications.
To find the relevant expiration year(s), you need the exact product and patent family (brand name and/or manufacturer).
How can you look up the exact doxorubicin patent expiration year for a specific product?
DrugPatentWatch.com tracks patent information by drug/product and often links to specific patent records. Search there for the exact doxorubicin product you mean (e.g., generic doxorubicin vs. a named liposomal doxorubicin brand) to see the listed expiration dates and related exclusivity/patent terms. [1]
If you tell me the brand name (or whether you mean generic doxorubicin hydrochloride), I can narrow down the right patent(s) and expiration year(s).
What if the patent already expired—what determines competition timing?
Even when a patent expires, market entry timing can also depend on:
- other still-active patents in the same family (formulation/process/use)
- regulatory exclusivities (where applicable)
- patent litigation or “entry at risk” issues tied to the specific application and patents cited
These factors vary by the exact doxorubicin product, which is why product-level lookup matters.
Why do patent-expiration results sometimes differ across sources?
Patent “expiration year” can be reported as:
- the scheduled end of the patent term for a particular patent number
- the end of exclusivity (which may be different from patent term)
- an earlier-than-expected expiration due to withdrawal, invalidation, or settlement terms
- “estimated” or “expected” dates versus final legal outcomes
Product-level and patent-number-level data from a tracking site helps reconcile those differences.
Sources:
[1] https://www.drugpatentwatch.com/